CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel | Blood | American Society of Hematology

An analysis of 20 patients who relapsed post Axi-Cel CAR-T looked at patterns and mechanism of relapse. About 30% of patients relapse with Cd19 negative disease. Cd19 negative relapses were more common in patients with lower pretreatment tumor burden, and those with a longer time to relapse (9 vs 3 months).

Read the full article here

Related Articles